Enzepi

RSS

Withdrawn

This medicine's authorisation has been withdrawn

pancreas powder
MedicineHumanWithdrawn

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 19 July 2017, the European Commission withdrew the marketing authorisation for Enzepi (pancreas powder) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Allergan Pharmaceuticals International Ltd, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Enzepi was granted marketing authorisation in the EU on 29 June 2016 as an enzyme replacement treatment for exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. The marketing authorisation was initially valid for a 5-year period. There is no impact on patients expected as Enzepi was not commercially available in Europe. 

The European Public Assessment Report (EPAR) for Enzepi is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (621.78 KB - PDF)

Amharc

español (ES) (540.43 KB - PDF)

Amharc

čeština (CS) (604.89 KB - PDF)

Amharc

dansk (DA) (536.24 KB - PDF)

Amharc

Deutsch (DE) (543.01 KB - PDF)

Amharc

eesti (ET) (535.46 KB - PDF)

Amharc

ελληνικά (EL) (625.77 KB - PDF)

Amharc

français (FR) (541.13 KB - PDF)

Amharc

hrvatski (HR) (559.2 KB - PDF)

Amharc

italiano (IT) (540.18 KB - PDF)

Amharc

latviešu (LV) (594.41 KB - PDF)

Amharc

lietuvių (LT) (562 KB - PDF)

Amharc

magyar (HU) (597.75 KB - PDF)

Amharc

Malti (MT) (606.17 KB - PDF)

Amharc

Nederlands (NL) (1003.58 KB - PDF)

Amharc

polski (PL) (603.85 KB - PDF)

Amharc

português (PT) (540.48 KB - PDF)

Amharc

română (RO) (564.35 KB - PDF)

Amharc

slovenčina (SK) (603.73 KB - PDF)

Amharc

slovenščina (SL) (597.53 KB - PDF)

Amharc

suomi (FI) (535.49 KB - PDF)

Amharc

svenska (SV) (537.16 KB - PDF)

Amharc

Product information

български (BG) (1.75 MB - PDF)

Amharc

español (ES) (931.36 KB - PDF)

Amharc

čeština (CS) (1.44 MB - PDF)

Amharc

dansk (DA) (906.51 KB - PDF)

Amharc

Deutsch (DE) (930.41 KB - PDF)

Amharc

eesti (ET) (976.01 KB - PDF)

Amharc

ελληνικά (EL) (1.83 MB - PDF)

Amharc

français (FR) (935.97 KB - PDF)

Amharc

hrvatski (HR) (973.31 KB - PDF)

Amharc

italiano (IT) (925.82 KB - PDF)

Amharc

latviešu (LV) (1.51 MB - PDF)

Amharc

lietuvių (LT) (1012.36 KB - PDF)

Amharc

magyar (HU) (1.45 MB - PDF)

Amharc

Malti (MT) (1.5 MB - PDF)

Amharc

Nederlands (NL) (1.53 MB - PDF)

Amharc

polski (PL) (1.49 MB - PDF)

Amharc

português (PT) (913.38 KB - PDF)

Amharc

română (RO) (1.02 MB - PDF)

Amharc

slovenčina (SK) (1.45 MB - PDF)

Amharc

slovenščina (SL) (1.41 MB - PDF)

Amharc

suomi (FI) (901.4 KB - PDF)

Amharc

svenska (SV) (907.25 KB - PDF)

Amharc

Íslenska (IS) (912.11 KB - PDF)

Amharc

norsk (NO) (952.94 KB - PDF)

Amharc
Latest procedure affecting product information:T/01
02/09/2016
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (596.25 KB - PDF)

Amharc

español (ES) (520.37 KB - PDF)

Amharc

čeština (CS) (561.4 KB - PDF)

Amharc

dansk (DA) (514.95 KB - PDF)

Amharc

Deutsch (DE) (527.99 KB - PDF)

Amharc

eesti (ET) (520.86 KB - PDF)

Amharc

ελληνικά (EL) (565.89 KB - PDF)

Amharc

français (FR) (536.94 KB - PDF)

Amharc

hrvatski (HR) (551.61 KB - PDF)

Amharc

italiano (IT) (519.21 KB - PDF)

Amharc

latviešu (LV) (567.89 KB - PDF)

Amharc

lietuvių (LT) (562.34 KB - PDF)

Amharc

magyar (HU) (584.06 KB - PDF)

Amharc

Malti (MT) (561.52 KB - PDF)

Amharc

Nederlands (NL) (975.32 KB - PDF)

Amharc

polski (PL) (559.86 KB - PDF)

Amharc

português (PT) (521.29 KB - PDF)

Amharc

română (RO) (548.73 KB - PDF)

Amharc

slovenčina (SK) (583.82 KB - PDF)

Amharc

slovenščina (SL) (542.36 KB - PDF)

Amharc

suomi (FI) (516.06 KB - PDF)

Amharc

svenska (SV) (512.27 KB - PDF)

Amharc

Íslenska (IS) (522.31 KB - PDF)

Amharc

norsk (NO) (509.71 KB - PDF)

Amharc

Product details

Name of medicine
Enzepi
Active substance
pancreas powder
International non-proprietary name (INN) or common name
pancreas powder
Therapeutic area (MeSH)
Exocrine Pancreatic Insufficiency
Anatomical therapeutic chemical (ATC) code
A09AA02

Pharmacotherapeutic group

Digestives, incl. enzymes

Therapeutic indication

Pancreatic enzyme replacement treatment in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer).
Enzepi is indicated in infants, children, adolescents and adults.

Authorisation details

EMA product number
EMEA/H/C/002070
Marketing authorisation holder
Allergan Pharmaceuticals International Limited

Clonshaugh Industrial Estate
Coolock
Dublin 17
Ireland

Marketing authorisation issued
29/06/2016
Revision
1

Assessment history

This page was last updated on

Share this page